DUBLIN, September 6, 2016 /PRNewswire/ --
Afimmune will today present an abstract entitled "DS102: a bioactive lipid for the treatment of chronic pulmonary disorders" at the European Respiratory Society in London, United Kingdom.
Afimmune is planning to initiate an Oral DS102 Phase IIa study in patients with Chronic Obstructive Pulmonary Disease (COPD) later this year. Separately, a Phase IIa study with Oral DS102 will also be conducted in patients with Non-Alcoholic Steatohepatitis (NASH).
Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on inflammatory conditions of the human primary organs including the liver and the lung. DS102 was recently spun out by DS Biopharma into Afimmune.